Add BrightSurf on Google Email

Newest medicines work just as well at half dosage for stable psoriasis

A study by Radboud University Medical Center found that 75% of patients with stable psoriasis can safely reduce their biologic medication dosage by half, achieving similar symptom control. This reduction in dosage leads to fewer injections and saves up to €8,500 per patient per year.

SourceRadboud University Medical Center·JournalThe Lancet Regional Health - Europe·TypeRandomized controlled/clinical trial·DateJun 1, 2026

Global rules could cut costs and speed access to GLP-1 drugs

A study from UC San Francisco researchers reveals that regulatory differences around the world are slowing the development and adoption of biosimilars. The lack of standardization in biosimilar approval processes is a major obstacle for these cheaper alternatives to expensive biologics, which could lower costs for patients.

SourceUniversity of California - San Francisco·JournalJAMA Health Forum·TypeLiterature review·DateMay 31, 2026

Hydroxychloroquine may protect people with skin lupus from heart health risks and metabolic complications, Johns Hopkins Medicine researchers find

Researchers found that hydroxychloroquine use was associated with better cardiovascular and cardiometabolic health outcomes in patients with discoid lupus erythematosus. The study also found a lower risk of hypertension, hyperlipidemia, type 2 diabetes, stroke, and coronary artery disease among hydroxychloroquine users.

SourceJohns Hopkins Medicine·JournalJournal of the American Academy of Dermatology·DateMay 26, 2026

Neuronal hyperacitivity triggers severe autoimmune brain disorder

A study published in Science Advances reveals that neuronal hyperactivity triggered by rogue antibodies is a key driver of the severe autoimmune brain disorder IgLON5 encephalitis. The research also highlights similarities between this condition and Alzheimer's disease, suggesting potential therapeutic targets.

SourceDZNE - German Center for Neurodegenerative Diseases·JournalScience Advances·TypeExperimental study·DateMay 15, 2026

Risk of celiac disease is not a reason to avoid antibiotics

A nationwide Swedish study of 27,789 individuals with confirmed celiac disease found no link between antibiotic use and increased risk of developing the autoimmune disorder. The study also revealed a higher proportion of prior antibiotics used among those with normal mucosa, suggesting other factors may contribute to its development.

SourceUniversity of Gothenburg·JournalClinical Gastroenterology and Hepatology·TypeObservational study·DateApr 28, 2026

Taming overactive immune systems with antibodies: hope for autoimmune diseases

A multi-institutional team has discovered a novel immune regulatory mechanism mediated by antibodies that selectively shut down overactive immune responses. The 'immune-induced TCR-like antibody' (iTab) can reduce disease severity and delay its onset in a mouse model of autoimmune disease.

SourceImmunology Frontier Research Center (IFReC) - The University of Osaka·JournalNature Communications·TypeExperimental study·DateApr 22, 2026

New BSC study reveals, for the first time, that the female immune system changes much more than that of men with age

A new study by the Barcelona Supercomputing Center reveals that women's immune systems undergo more pronounced changes with age, leading to a greater susceptibility to autoimmune diseases. In contrast, men experience less extensive immune system changes, but are at higher risk for certain blood cancers.

SourceBarcelona Supercomputing Center·JournalNature Aging·TypeData/statistical analysis·DateApr 10, 2026

New biomarker for immunoglobulin a nephropathy identified

Researchers have discovered a new biomarker for immunoglobulin A (IgA) nephropathy, which is an autoimmune disease that can lead to kidney failure. Complement pathway proteins, including CFHR1, were found to be overexpressed in patients with IgA nephropathy, suggesting a potential treatment target and diagnostic marker.

SourceFujita Health University·JournalScientific Reports·TypeExperimental study·DateMar 30, 2026

B-type natriuretic peptide as a predictor of kidney disease progression in diabetes

A recent study found that B-type natriuretic peptide is independently associated with chronic kidney disease progression in individuals with diabetes. Combining BNP with urinary markers such as UACR improves risk prediction, highlighting its potential role in early detection and management of kidney disease.

SourceJuntendo University Research Promotion Center·JournalDiabetes Research and Clinical Practice·TypeObservational study·DateMar 24, 2026

100,000 participants screened for early-stage type 1 diabetes in the EDENT1FI project

EDENT1FI has screened 100,000 children across Europe for early-stage type 1 diabetes, using standardized screening programs and harmonized data collection. The initiative aims to empower families to manage life with type 1 diabetes effectively and support children and adolescents with early-stage detection.

Why does the body deem some foods safe and others unsafe?

Researchers have identified three new proteins, called epitopes, that help the body determine 'safe' foods, aiding in food tolerance and allergy understanding. The epitopes were found in seed proteins from corn, wheat, and soybean, and interact with regulatory T cells to inform tolerance-or-rejection decisions.

SourceSalk Institute·JournalScience Immunology·DateMar 6, 2026

Macrophage immune cells need constant reminders to retain memories of prior infections

Researchers found that macrophages retain memories of previous infections due to persistent signaling molecules left behind, which can be reversed by blocking cytokine signaling pathways. This discovery suggests new ways to reduce the activity of misprogrammed macrophages contributing to autoimmune diseases.

SourceRockefeller University Press·JournalJournal of Experimental Medicine·TypeExperimental study·DateFeb 18, 2026

Inflammation and autoimmune-like dysfunction may play a role in heart failure

A recent study from Penn State College of Medicine researchers found that helper T cells, typically involved in fighting infections, become overly activated in failing human hearts, causing damage. The activation of these T cells highlights the impact of inflammation and immune dysfunction in heart failure.

SourcePenn State·JournalJournal of Molecular and Cellular Cardiology·TypeObservational study·DateJan 27, 2026

Itaconate modifications: mechanisms and applications

Researchers summarize itaconate biology highlighting its chemical reactivity and therapeutic potential in treating infectious diseases, sepsis, autoimmunity, neurodegenerative disorders. Itaconate exerts biological effects through post-translational modifications, altering protein activity and signaling pathways

SourceJournal of Intensive Medicine·JournalJournal of Intensive Medicine·TypeLiterature review·DateJan 15, 2026

“Recipe book” for reprogramming immune cells

Researchers have created a library of over 400 immune-related factors to reprogram rare immune cell populations. This technique allows for the systematic discovery of 'recipes' for specific immune cells, offering hope for unresponsive patients and advancing immunotherapy.

SourceLund University·JournalCell Systems·TypeExperimental study·DateJan 14, 2026

New mechanism links Epstein-Barr virus to MS

A new study from Karolinska Institutet reveals the Epstein-Barr virus can damage the brain and contribute to multiple sclerosis through molecular mimicry. The researchers found that cross-reactive T cells are significantly more common in people with MS, and targeting these cells may lead to new treatments.

SourceKarolinska Institutet·JournalCell·DateJan 13, 2026

Study proves the anti-inflammatory, analgesic, and anti-arthritic actions of a plant used in folk medicine

Researchers from Brazil confirm the safety and efficacy of Alternanthera littoralis (Joseph's Coat) in reducing inflammation and modulating inflammatory mediators. The study's findings support the plant's medicinal potential and suggest a safety profile at therapeutic doses.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalJournal of Ethnopharmacology·DateDec 10, 2025

Improving treatment for an autoimmune bleeding condition

A Phase III clinical trial found that over half of patients who received ianalumab for primary ITP maintained safe platelet counts without serious bleeding episodes for at least one year. The study suggests a new treatment option with the potential to improve long-term quality of life for patients.

SourceUniversity of Pennsylvania School of Medicine·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 9, 2025